Navigation Links
Pain Management For Your Pets, Key Information Every Pet Owner Should Know - Live Webcast to Pet Owners, March 13, 8:00 p.m. to 9:00 p.m. (EDT) Via Morris Animal Foundation
Date:3/3/2008

World-Renowned Pain Management Expert Robin Downing, DVM, Will Conduct Webcast For Pet Owners, Covering All Aspects Related to Pets and Pain

DENVER, March 3 /PRNewswire/ -- Morris Animal Foundation (MAF) will sponsor a live webcast for pet owners on pain management for their pets on March 13, 2008, from 8:00 p.m. to 9:00 p.m. (Eastern Daylight Time). The live webcast will cover all aspects of pain management, including common causes of pain, overlooked hidden causes of pain, anticipating and avoiding pain in your pets, communicating with your veterinarian and how to ask the right questions. Participate in the webcast at: http://www.MorrisAnimalFoundation.org/livechat. In addition, a webcast on pet pain directed to veterinarians takes place from 7:00 p.m. to 8:00 p.m. EDT. Both webcasts will be available indefinitely for global audiences on a non-live basis at the webcast address.

(http://www.newscom.com/cgi-bin/prnh/20040701/LAMAFLOGO)

Leading this webcast will be Robin Downing, DVM, a MAF Trustee and one of the world's leading experts on pain in animals. In 2005, Dr. Downing became the third veterinarian in the world to acquire diplomate credential from the American Academy of Pain Management. As of today, fewer than a dozen veterinarians worldwide hold this credential. Dr. Downing is founder and past president of the International Veterinary Academy of Pain Management and was co-chair of the task force that authored the "2007 AAHA/AAFP Pain Management Guidelines for Dogs and Cats." In 2006 she opened The Downing Center for Animal Pain Management, LLC, the only comprehensive pain management and pain prevention practice for pets in Northern Colorado. Contributing to the discussion will be Patricia Olson, DVM, Ph.D., president and CEO of Morris Animal Foundation. For more informatio
'/>"/>

SOURCE Morris Animal Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Pain Management For Pets, Key Strategies For Veterinarians - Live Webcast to Veterinarians, March 13, 7:00 p.m. to 8:00 p.m. (EDT) Via Morris Animal Foundation
2. Smith & Nephew Orthopaedic Reconstruction Global Management Team Announced
3. URAC Invites Health Management Industry, Public for Comments on Changes to Its Core Accreditation Standards
4. AlphaDetail, Inc. Expands Management Team
5. Groundbreaking Sign Chi Do Stress Management System Introduced by Dr. Anne Borik Now Available to the Public
6. Jackson Lewis to Support Presagias Integrated Absence & Disability Management Solution
7. Medication Management Systems Names New President and COO
8. Siemens Signs New Revenue Cycle Management Customers
9. Keane Wins Revenue Cycle Management Implementation With Mount Sinai Hospital of Queens
10. Antares Management Solutions Earns Top ISO Re-Certification
11. Inclinix, Inc. Announces Executive Management Team Changes
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10